Profile data is unavailable for this security.
About the company
Kaleido Biosciences, Inc. is a clinical-stage healthcare company focused on microbiome organs to treat disease and improve human health. The Company’s product candidates are Microbiome Metabolic Therapies (MMTs), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of existing microbes. It is advancing a pipeline of MMT candidates to address a range of diseases and conditions with unmet patient needs. KB109 and KB174 are the MMT candidates for development for the prevention of infections caused by multi-drug resistant (MDR) bacteria. The nomination of these candidates resulted from their performance relative to a range of other MMTs in ex vivo screening of microbiome samples from healthy volunteers as well as microbiome samples from intensive care unit patients in an experimental set-up that specifically focused on determining the potential of MMTs to decrease the relative abundance of a panel of pathogenic bacteria.
- Revenue in USD (TTM)1.10m
- Net income in USD-90.29m
- Incorporated2015
- Employees76.00
- LocationKaleido Biosciences Inc18 Crosby DrBEDFORD 01730-1402United StatesUSA
- Phone+1 (617) 674-9000
- Fax+1 (302) 655-5049
- Websitehttps://kaleido.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kaleido Biosciences Inc | 1.10m | -90.29m | 40.00 | 76.00 | -- | 0.00 | -- | 0.00004 | -2.16 | -2.16 | 0.0264 | 0.249 | 0.0202 | -- | -- | 14,526.32 | -164.94 | -121.82 | -285.99 | -152.67 | -- | -- | -8,178.26 | -16,716.79 | -- | -31.69 | 0.6716 | -- | 13.23 | -- | -10.62 | -- | 42.08 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Pennsylvania State Employees' Retirement Systemas of 31 Dec 2021 | 8.93k | 0.00% |
| Bay Harbor Wealth Management LLCas of 31 Mar 2024 | 2.30k | 0.00% |
